A Multi-center, Open-label Phase IB Study of Escalating Doses of RO5045337, an Oral Small Molecule MDM2 Antagonist, in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Maximum tolerated dose/dose-limiting toxicities
approximately 12 months
Yes
Clinical Trials
Study Director
Hoffmann-La Roche
United States: Food and Drug Administration
NP28021
NCT01605526
May 2012
June 2013
Name | Location |
---|---|
Fountain Valley, California 92708 | |
Philadelphia, Pennsylvania 19104 | |
Hackensack, New Jersey 07601 | |
Boston, Massachusetts | |
Salt Lake City, Utah 84112 |